Ligand-based design, molecular dynamics and ADMET studies of suggested SARS-CoV-2 M pro inhibitors.
| Autor: | Mohamed NM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Modern University for Technology and Information (MTI) Egypt nada.mostafa@pharm.mti.edu.eg., Ali EMH; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Modern University for Technology and Information (MTI) Egypt nada.mostafa@pharm.mti.edu.eg.; University of Science & Technology (UST) Yuseong-gu Daejeon 34113 Republic of Korea., AboulMagd AM; Pharmaceutical Chemistry Department, Faculty of Pharmacy, Nahda University (NUB) Beni-Suef Egypt. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | RSC advances [RSC Adv] 2021 Jan 22; Vol. 11 (8), pp. 4523-4538. Date of Electronic Publication: 2021 Jan 22 (Print Publication: 2021). |
| DOI: | 10.1039/d0ra10141a |
| Abstrakt: | Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been the choice of recent studies worldwide to control its pandemic. Given the similarity with the earlier SARS-CoV, it is possible to use the previously reported inhibitors to develop a new treatment for the current attack of SARS-CoV-2. This study used the formerly published SARS-CoV M pro small-molecule protease inhibitors to develop a pharmacophore model in order to design new ligands. Several strategies and scaffolds were evaluated in silico giving rise to ten newly designed compounds. Molecular docking and dynamics simulations were performed on M pro enzyme in its active site to evaluate the newly designed ligands I-X. The results obtained from this work showed that compounds III-VI had a better molecular docking score than the co-crystallized ligand baicalein (3WL) giving -5.99, -5.94, -6.31, -6.56 and -5.74 kcal mol -1 , respectively. Moreover, they could bind to the M pro binding site better than I, II and VII-X. The most promising chromen-2-one based compounds V-VI had sufficiently acceptable physicochemical and ADMET properties to be considered new leads for further investigations. This new understanding should help to improve predictions of the impact of new treatments on COVID-19. Competing Interests: We declare that we have no conflicts of interest. (This journal is © The Royal Society of Chemistry.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|